How to manage intravenous vinflunine in cancer patients with renal impairment: Results of a pharmacokinetic and tolerability phase i study
British Journal of Clinical Pharmacology, ISSN: 0306-5251, Vol: 77, Issue: 3, Page: 498-508
2014
- 8Citations
- 27Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations8
- Citation Indexes8
- CrossRef8
- Captures27
- Readers27
- 27
Article Description
Aims Vinflunine (VFL) ditartrate, a novel tubulin-targeted inhibitor, is registered for the treatment of patients with advanced or metastatic urothelial transitional cell carcinoma. This phase I study assessed the effect of renal impairment on the pharmacokinetics and tolerability of VFL. Methods VFL was infused in patients with advanced/metastatic solid tumours once every 3 weeks with anticipated dose reduction on the first cycle stratified according to the creatinine clearance (CL) values. Pharmacokinetic data were collected on the first two cycles in renally impaired patients (CL ≤ 60 ml min) and were compared with a control cohort of patients (CL > 60 ml min). Results Thirty-three patients (46-86 years) were treated, 13 in group 1 (40 ml min ≤ CL ≤ 60 ml min) and 20 in group 2 (20 ml min ≤ CL < 40 ml min). The renal dysfunction induced a mean decrease in VFL clearance of 12% in group 1 and 28% in group 2, compared with the control group. The anticipated dose reduction given in renally impaired patients (i.e. 280 mg m and 250 mg m in groups 1 and 2, respectively) yielded similar drug exposure to control patients. The tolerance profile of VFL in patients with renal dysfunction was similar to that observed in patients with CL > 60 ml min. Conclusion In conclusion, the recommended doses of intravenous VFL administered once every 3 weeks in cancer patients with renal impairment are 280 mg m when CL is between 40 and 60 ml min and 250 mg m when CL is between 20 and <40 ml min. © 2013 The British Pharmacological Society.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84894475296&origin=inward; http://dx.doi.org/10.1111/bcp.12218; http://www.ncbi.nlm.nih.gov/pubmed/24283925; https://onlinelibrary.wiley.com/doi/10.1111/bcp.12218; http://doi.wiley.com/10.1111/bcp.12218; https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.12218
Wiley
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know